IN VIVO MITIGATION OF SCOPOLAMINE-INDUCED CHOLINERGIC DYSFUNCTION AND OXIDATIVE STRESS BY SELECTED LACTOBACILLUS STRAINS

BULACIOS GA; NAJA JR; CATALDO PG; MARTINEZ URQUIZA P; ELEAN MD; POSSE DE CHAVES E; TARANTO MP; BEAQUIS J; HEBERT EM; SAAVEDRA L

Rosario, Santa Fe

Congreso; 59 del Congreso Anual de la Sociedad Argentina de Investigaciones en Bioquímica y Biología Molecular; 2023

SAIB

Life expectancy has increased exponentially over the last 50 years. This extended lifespan has led to theemergence of age-related disorders, with dementia taking center stage. Among the various forms ofdementia, Alzheimer´s disease (AD) stands out as the most common, accounting for 60-70% of cases.Currently, there is no definitive treatment for this condition, and all drugs and interventions focusingsolely on symptom alleviation, primarily through cholinesterase inhibitors and memantine. In thiscontext, scientists have embarked on a quest to uncover agents or combination of them capable offorestalling or enhancing the quality of life for those affected by this condition. Recent research hasspotlighted nutritional interventions and the burgeoning field of probiotics, which hold promise formental health. In the present study, we evaluated the effect of daily oral administration of two probioticstrains: Lactobacillus delbrueckii subsp. lactis CRL 581 (1x108), an in vitro acetylcholinesterase (AChE)inhibitor, and Levilactobacillus brevis CRL 2013 (1x109), an efficient gamma-aminobutyric acid (GABA)producing strain. This administration spanned a period of 30 days and aimed to investigate theirimpact on oxidative stress and cholinergic dysfunction within a scopolamine-induced mice model.Scopolamine, acting as a cholinergic receptor antagonist, induced memory loss, cognitive impairment,and elevated AChE activity, thereby replicating some pathological alterations observed in AD. AChEactivity exhibited a significant increase in brain homogenates of mice treated with scopolaminecompared to the control group. Both probiotic strains demonstrated the ability to decrease AChEactivity, with CRL 581 showing particularly noteworthy efficacy. Furthermore, CRL 2013 administrationincreased catalase activity in mice brains. In females, solely treatments with CRL 581 strain showed adecrease in MDA levels, an end-product of lipid peroxidation, whereas in males, both strains displayedthe capacity to reduce it. No significant differences were observed in GSH activity across all groups.Data from the shotgun proteomic of scopolamine- and psychobiotics- treated brain homogenatesrevealed distinctly and unique differential expression patterns in each group. These findings stronglysupport the potential development of a functional supplement using t, offering a promisingnon-pharmacological intervention for individuals affected by Alzheimer´s disease